<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742182</url>
  </required_header>
  <id_info>
    <org_study_id>Circadian Rhythms in PD</org_study_id>
    <secondary_id>1K23NS072283-01A1</secondary_id>
    <nct_id>NCT01742182</nct_id>
  </id_info>
  <brief_title>Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease</brief_title>
  <official_title>Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disruption of sleep and alertness is one of the most disabling non-motor symptoms of
      Parkinson's disease (PD). Mechanisms leading to impaired sleep and alertness in PD are not
      well understood, and treatment options remain limited. The proposed research will examine
      markers of the circadian system, sleepiness and sleep quality in PD patients and healthy
      controls. Further, the project will examine effects of bright light exposure on circadin
      function, sleep and alertness in PD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>circadian rhythm of melatonin</measure>
    <time_frame>June 2012- May 2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>June 2012- May 2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daytime Somnolence</measure>
    <time_frame>June 2012- May 2017</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD patients without sleep problems</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD patients with sleep problems</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>light exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD patients with sleep problem</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>light exposure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Light exposure</intervention_name>
    <arm_group_label>PD patients with sleep problem</arm_group_label>
    <arm_group_label>PD patients with sleep problems</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank
             Criteria;

          2. PD Hoehn and Yahr stage 2-4;

          3. Pittsburgh Sleep Quality Index (PSQI) score &gt;5 in group 1, and ≤5 in group 2;

          4. Epworth Sleepiness Scale (ESS) score ≥10 in group 1, and &lt;10 in group 2;

        Control participants will be matched for gender and age with PD participants.

        Exclusion Criteria:

          1. Atypical or secondary forms of Parkinsonism;

          2. Cognitive impairment as determined by the Mini-Mental State Examination (MMSE) score
             of ≤ 26;

          3. Presence of depression defined as the Beck Depression Inventory (BDI) score &gt;14;

          4. Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to
             taper these drugs and will become eligible at least 4 weeks after the taper is
             completed;

          5. Use of SSRIs / SNRIs antidepressants, unless the participant has been on a stable dose
             for at least 3 months prior to the screening;

          6. Use of medications known to affect melatonin secretion;

          7. Unstable/serious medical illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandar Videnovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>February 15, 2020</last_update_submitted>
  <last_update_submitted_qc>February 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Aleksandar Videnovic, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Excessive Daytime Sleepiness</keyword>
  <keyword>Circadian Rhythms</keyword>
  <keyword>Light Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

